Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 4:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 363 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Disabilities Multiple Clear all
Completed No phase listed Observational

Characteristics of Prader-Willi Syndrome and Early-onset Morbid Obesity

NCT00375089
View directory record Official record
Conditions
Prader-Willi Syndrome, Obesity
Interventions
Group 1, Group 2
Other
Lead sponsor
University of Florida
Other
Eligibility
Up to 60 Years
Enrollment
392 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
4
States / cities
Orange, California • Gainesville, Florida • Kansas City, Kansas + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2014 · Synced Oct 22, 2026, 4:50 AM EDT
Completed No phase listed Observational

A Non-Drug Study of The Suitability of Neurocognitive Tests And Functioning Scales For The Measurement of Cognitive And Functioning Changes in Individuals With Down Syndrome

NCT01580384
View directory record Official record
Conditions
Down Syndrome
Interventions
Not listed
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
12 Years to 30 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
Tucson, Arizona • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 3, 2015 · Synced Oct 22, 2026, 4:50 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment

NCT06239116
View directory record Official record
Conditions
Hypothalamic Obesity, Prader-Willi Syndrome, PWS
Interventions
Part A: RM-718 or placebo (matched to specific RM-718 dose cohort), Part B: RM-718 or placebo (matched to specific RM-718 dose cohort), Part C: RM-718, Part D: RM-718
Drug
Lead sponsor
Rhythm Pharmaceuticals, Inc.
Industry
Eligibility
12 Years to 65 Years
Enrollment
111 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
7
States / cities
Birmingham, Alabama • Chicago, Illinois • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 22, 2026, 4:50 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

HomeGrown: A Family-based Lifestyle Intervention to Support Healthy Development of Young Children With Down Syndrome

NCT07296861
View directory record Official record
Conditions
Down Syndrome, Child Obesity
Interventions
The HomeGrown, Waitlist
Behavioral · Other
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
Not listed
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 22, 2026, 4:50 AM EDT
Completed Phase 2 Interventional Results available

Dilated Versus Non-Dilated Wavefront Corrections for Patients With Down Syndrome

NCT05059041
View directory record Official record
Conditions
Down Syndrome, Refractive Errors
Interventions
Dilated Refraction, Non-Dilated Refraction
Device
Lead sponsor
Ohio State University
Other
Eligibility
5 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Columbus, Ohio • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 22, 2026, 4:50 AM EDT
Recruiting Not applicable Interventional

Brain Outcomes With Lifestyle Change in Down Syndrome

NCT05985486
View directory record Official record
Conditions
Down Syndrome, Alzheimer Disease, Obesity
Interventions
Diet, Health Education
Behavioral
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 64 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 22, 2026, 4:50 AM EDT
Recruiting No phase listed Observational

Patterns of Neurodevelopmental Disorders

NCT06213090
View directory record Official record
Conditions
Neurodevelopmental Disorders, Autism Spectrum Disorder, Pediatric Autoimmune Neuropsychiatric Disorder Associated With Streptococcal Infection, Pediatric Acute-Onset Neuropsychiatric Syndrome, Down Syndrome, Epilepsy, Mitochondrial Encephalomyopathies, Cerebral Folate Deficiency
Interventions
Not listed
Lead sponsor
Richard Frye
Other
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 22, 2026, 4:50 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of Setmelanotide in Patients With Prader-Willi Syndrome

NCT06772597
View directory record Official record
Conditions
Prader-Willi Syndrome, Obesity, Hyperphagia
Interventions
Setmelanotide
Drug
Lead sponsor
Rhythm Pharmaceuticals, Inc.
Industry
Eligibility
6 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 22, 2026, 4:50 AM EDT
Completed Phase 2 Interventional Results available

A Study of GLWL-01 in Patients With Prader-Willi Syndrome

NCT03274856
View directory record Official record
Conditions
Prader-Willi Syndrome
Interventions
GLWL-01, Placebo
Drug
Lead sponsor
GLWL Research Inc.
Other
Eligibility
16 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
4
States / cities
San Diego, California • Gainesville, Florida • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2020 · Synced Oct 22, 2026, 4:50 AM EDT
Enrolling by invitation Phase 1 Interventional

Sensitivity of the NIH Toolbox to Stimulant Treatment in Intellectual Disabilities

NCT05301361
View directory record Official record
Conditions
Intellectual Disability, Fragile X Syndrome, Down Syndrome, Attention Deficit Hyperactivity Disorder
Interventions
Methylphenidate Oral Solution
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
6 Years to 24 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Sacramento, California • Chicago, Illinois • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Oct 22, 2026, 4:50 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Blood Flow in Individuals With Down Syndrome

NCT03590665
View directory record Official record
Conditions
Down Syndrome
Interventions
Hand grip exercise and lower body negative pressure
Other
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 45 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 15, 2019 · Synced Oct 22, 2026, 4:50 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Natural History of Dysregulation and Aging of the Immune System in People With Trisomy 21 With and Without Thymectomy

NCT07416201
View directory record Official record
Conditions
Down Syndrome
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Year to 120 Years
Enrollment
700 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2040
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 22, 2026, 4:50 AM EDT
Completed Phase 3 Interventional Results available

Phase 3 Study of Intranasal Carbetocin (LV-101) in Patients With Prader-Willi Syndrome

NCT03649477
View directory record Official record
Conditions
Prader-Willi Syndrome
Interventions
3.2 mg intranasal carbetocin, 9.6 mg intranasal carbetocin, placebo
Drug
Lead sponsor
Levo Therapeutics, Inc.
Industry
Eligibility
7 Years to 18 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
19
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Oct 22, 2026, 4:50 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Non-invasive Prenatal Diagnostic Validation Study

NCT01574781
View directory record Official record
Conditions
Chromosome 13 Aneuploidy, Chromosome 18 Aneuploidy, Chromosome 21 Aneuploidy, Sex Chromosome Aberrations, Other Microdeletions
Interventions
Blood draw, Cheek swab/Saliva Sampling
Procedure
Lead sponsor
Natera, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,781 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Redwood City, California
Source: ClinicalTrials.gov public record
Updated Jul 2, 2013 · Synced Oct 22, 2026, 4:50 AM EDT
Completed Not applicable Interventional Results available

Investigating the Experience of Living With Down Syndrome and Obstructive Sleep Apnea Syndrome (Stage 1)

NCT04124471
View directory record Official record
Conditions
Down Syndrome, Obstructive Sleep Apnea
Interventions
Open-ended semi-structured interviews
Behavioral
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
6 Years to 17 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 25, 2023 · Synced Oct 22, 2026, 4:50 AM EDT
Completed No phase listed Observational

A Screening Protocol to Assess Adults and Adolescents With Down Syndrome for Eligibility For Upcoming Study of RG1662 (Study BP27832)

NCT01920633
View directory record Official record
Conditions
Down Syndrome
Interventions
Not listed
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
12 Years to 30 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
9
States / cities
La Jolla, California • Decatur, Georgia • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2017 · Synced Oct 22, 2026, 4:50 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

NCT03914625
View directory record Official record
Conditions
B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Down Syndrome
Interventions
Asparaginase Erwinia chrysanthemi, Blinatumomab, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Leucovorin Calcium, Mercaptopurine, Mercaptopurine Oral Suspension, Methotrexate, Pegaspargase, Prednisolone, Prednisone, Radiation Therapy, Thioguanine, Vincristine Sulfate
Drug · Biological · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
365 Days to 31 Years
Enrollment
6,720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
201
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 153 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 22, 2026, 4:50 AM EDT
Completed Phase 2 Interventional Results available

Intranasal Oxytocin vs. Placebo for the Treatment of Hyperphagia in Prader-Willi Syndrome

NCT03197662
View directory record Official record
Conditions
Prader-Willi Syndrome, Hyperphagia
Interventions
Intranasal Oxytocin (IN-OXT), Matched Placebo
Drug
Lead sponsor
Eric Hollander
Other
Eligibility
5 Years to 17 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Feb 7, 2025 · Synced Oct 22, 2026, 4:50 AM EDT
Terminated Not applicable Interventional

Post-Intensive Care Transitional Care, Rehabilitation, and Family-Support

NCT06501365
View directory record Official record
Conditions
Intensive Care Unit Syndrome, Disabilities Multiple, Critical Illness, Caregiver Burden
Interventions
Post Intensive Care Transitions Rehabilitation and Family Support (PIC-TRFS), Enhanced Usual Care Control
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
50 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 22, 2026, 4:50 AM EDT
Recruiting Not applicable Interventional

Harness-based Mobility Intervention for Infants With Down Syndrome

NCT06219863
View directory record Official record
Conditions
Down Syndrome
Interventions
Body weight supported harness
Behavioral
Lead sponsor
Boston University Charles River Campus
Other
Eligibility
Up to 2 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 22, 2026, 4:50 AM EDT
Completed Not applicable Interventional

Power Over Pain (POP) Study

NCT01800604
View directory record Official record
Conditions
Multiple Sclerosis, Spinal Cord Injury, Chronic Pain, Other and Unspecified Amputation Stump Complications, Muscular Dystrophies, Low Back Pain
Interventions
Pain Self-Management Intervention #1, Pain Self-Management Intervention #2, Pain Self-Management Intervention #3, Pain Self-Management Intervention #4
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 17, 2018 · Synced Oct 22, 2026, 4:50 AM EDT
Recruiting Not applicable Interventional

Pediatric Medication Therapy Management Trial

NCT05761847
View directory record Official record
Conditions
Child, Only, Disabilities Multiple, Medication Interaction, Medication Compliance, Medication Administered in Error
Interventions
Pediatric Medication Therapy Management (pMTM)
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
2 Years to 18 Years
Enrollment
371 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 22, 2026, 4:50 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Digital Dysmorphology Project

NCT02651493
View directory record Official record
Conditions
Down Syndrome
Interventions
photographs
Device
Lead sponsor
Kevin Cleary
Other
Eligibility
Up to 18 Years
Enrollment
750 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2023
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 1, 2023 · Synced Oct 22, 2026, 4:50 AM EDT
Completed Phase 2 Interventional

A Study of RG1662 in Adults and Adolescents With Down Syndrome (CLEMATIS)

NCT02024789
View directory record Official record
Conditions
Down Syndrome
Interventions
Placebo, RG1662
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
12 Years to 30 Years
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
9
States / cities
La Jolla, California • Sacramento, California • Decatur, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2017 · Synced Oct 22, 2026, 4:50 AM EDT